Urinary and Male Reproductive System Tumors

UROLOGIC CANCERS

Urologic cancers are cancers of the urinary tract, including bladder cancer, renal (kidney) cancer and those specific to men, such as prostate cancer and testicular cancer. Prostate cancer is one of the most commonly diagnosed malignancies in men.

The current treatment landscape for urologic cancers includes surgery, radiation therapy, chemotherapy and androgen deprivation therapy (ADT) for prostate cancer. Patients, however, often face recurrences and resistance to these treatments. Novel biomarkers help with prognosis of current treatments and development of targeted therapies and immunotherapies to improve therapeutic interventions.

PROSCAN®

Targets 40 key genes in prostate cancer

  • Analyzes key genes in androgen receptor pathway and PI3K-mTOR pathway
  • Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers
  • Identifies androgen receptor (AR) mutations and elucidates drug resistance mechanisms
  • Detects BRCA1/2 deficiency to predict potential response to PARP inhibitors
  • Evaluates microsatellite instabilities (MSI) and mismatch repair deficiency (dMMR) to better inform immunotherapy decisions
  • Assesses genetic predisposition to cancers
WHO IS IT FOR
  • Prostate cancer patients seeking personalized medicine
  • Patients with recurrent metastatic castration-resistant prostate cancer (mCRPC)
SAMPLE TYPES
Icon Tumour Tissue

Tumor tissue (FFPE block/slides, or frozen tissue)

Icon Fine Needle Biopsy

Fine needle biopsy

Icon Liquid Biopsy

Liquid biopsy (plasma and others)

UROCAN®

Targets 55 key genes in bladder and renal cancer

  • Comprehensive testing of PDGFRA/B, c-KIT, RET receptor tyrosine kinase variants (amplification, point mutation and fusion) to guide targeted therapy
  • Analyzes key genes in PI3K-mTOR and MAPK pathways
  • Evaluates microsatellite instabilities (MSI) and mismatch repair deficiency (dMMR) to better inform immunotherapy decisions
  • Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers
  • Assesses genetic predisposition to cancers
WHO IS IT FOR
  • Urologic cancer patients seeking personalized medicine
  • Urologic cancer patients with recurrent disease
SAMPLE TYPES
Icon Tumour Tissue

Tumor tissue (FFPE block/slides, or frozen tissue)

Icon Fine Needle Biopsy

Fine needle biopsy

Icon Liquid Biopsy

Liquid biopsy (plasma and others)

LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.

Learn more about our products and services or contact us today to discuss how we can partner together.

Contact Us